• Archana Singh-Manoux, Martin J Shipley, Joshua A Bell, Marianne Canonico, Alexis Elbaz, and Mika Kivimäki.
• INSERM U1018 Centre de recherche en Epidémiologie et Santé des Populations (Singh-Manoux, Canonico, Elbaz), Hôpital universitaire Paul-Brousse, Villejuif, France; Department of Epidemiology and Public Health (Shipley, Bell, Kivimäki), University College London, London, UK Archana.Singh-Manoux@inserm.fr.
• CMAJ. 2017 Mar 13; 189 (10): E384-E390.

BackgroundThe inflammatory biomarker α1-acid glycoprotein (AGP) was found to have the strongest association with 5-year mortality in a recent study of 106 biomarkers. We examined whether AGP is a better biomarker of mortality risk than the more widely used inflammatory biomarkers interleukin-6 (IL-6) and C-reactive protein (CRP).MethodsWe analyzed data for 6545 men and women aged 45-69 (mean 55.7) years from the Whitehall II cohort study. We assayed AGP, IL-6 and CRP levels from fasting serum samples collected in 1997-1999. Mortality followup was until June 2015. Cox regression analysis was used to model associations of inflammatory biomarkers with all-cause, cardiovascular and cancer-related mortality.ResultsOver the mean follow-up of 16.7 years, 736 deaths occurred, of which 181 were from cardiovascular disease and 347 from cancer. In the model adjusted for all covariates (age, sex, socioeconomic status, body mass index, health behaviours and chronic disease), AGP did not predict mortality beyond the first 5 years of follow-up; over this period, IL-6 and CRP had stronger associations with mortality. When we considered all covariates and biomarkers simultaneously, AGP no longer predicted all-cause mortality over the entire follow-up period (adjusted hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.90-1.08). Only IL-6 predicted all-cause mortality (adjusted HR 1.22, 95% CI 1.12-1.33) and cancer-related mortality (adjusted HR 1.13, 95% CI 1.00-1.29) over the entire follow-up period, whereas CRP predicted only cardiovascular mortality (adjusted HR 1.30, 95% CI 1.06-1.61).InterpretationOur findings suggest that AGP is not a better marker of short-or long-term mortality risk than the more commonly used biomarkers IL-6 and CRP.© 2017 Canadian Medical Association or its licensors.

25 keywords...

hide…